Contemporary grading for prostate cancer: Implications for patient care

European Urology

Volumn 63, Issue 5, 2013, Pages 892-901

  Brimo, Fadi ^a   Montironi, Rodolfo ^b   Egevad, Lars ^c   Erbersdobler, Andreas ^d   Lin, Daniel W ^e   Nelson, Joel B ^f   Rubin, Mark A ^g   Van Der Kwast, Theo ^h   Amin, Mahul ⁱ   Epstein, Jonathan I ^j  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY HEALTH NETWORK   (Canada)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j JOHNS HOPKINS HOSPITAL   (United States)

more..

Author keywords

Cryosurgery; Gleason grading; Prostatectomy; Radiation; Ultrasonic therapy; Watchful waiting

Indexed keywords

AGGRESSION; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CRYOABLATION; CRYOSURGERY; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MALE; METASTASIS; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; SALVAGE THERAPY; SURVIVAL RATE; TRANSURETHRAL RESECTION;

EID: 84876057180     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.10.015     Document Type: Review

References (67)

1. D.F. Gleason Classification of prostatic carcinomas Cancer Chemother Rep 50 1966 125 128
2. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, and L.L. Egevad The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242
3. S.W. Fine, and J.I. Epstein A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score J Urol 179 2008 1335 1338 discussion 1338-9
4. C.C. Pan, S.R. Potter, A.W. Partin, and J.I. Epstein The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system Am J Surg Pathol 24 2000 563 569
5. M. Latour, M.B. Amin, and A. Billis Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology Am J Surg Pathol 32 2008 1532 1539
6. S.W. Fine, M.B. Amin, and D.M. Berney A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens Eur Urol 62 2012 20 39
7. F. Dong, C. Wang, and A.B. Farris Impact on the clinical outcome of prostate cancer by the 2005 International Society of Urological Pathology modified Gleason grading system Am J Surg Pathol 36 2012 838 843
8. O.N. Gofrit, K.C. Zorn, G.D. Steinberg, G.P. Zagaja, and A.L. Shalhav The Will Rogers phenomenon in urological oncology J Urol 179 2008 28 33
9. Pierorazio PM, Ross AE, Lin BM, et al. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int. In press. http://dx.doi.org/10.1111/j.1464- 410X.2012.10986.x.
10. L. Egevad, R. Mazzucchelli, and R. Montironi Implications of the International Society of Urological Pathology modified Gleason grading system Arch Pathol Lab Med 136 2012 426 434
11. G.M. Kunz Jr., and J.I. Epstein Should each core with prostate cancer be assigned a separate Gleason score? Hum Pathol 34 2003 911 914
12. C.K. Poulos, J.K. Daggy, and L. Cheng Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites Mod Pathol 18 2005 228 234
13. L.P. Kunju, S. Daignault, J.T. Wei, and R.B. Shah Multiple prostate cancer cores with different Gleason grades submitted in the same specimen container without specific site designation: should each core be assigned an individual Gleason score? Hum Pathol 40 2009 558 564
14. H.K. Park, G. Choe, S.S. Byun, H.W. Lee, S.E. Lee, and E. Lee Evaluation of concordance of Gleason score between prostatectomy and biopsies that show more than two different Gleason scores in positive cores Urology 67 2006 110 114
15. B.J. Trock, C.C. Guo, M.L. Gonzalgo, A. Magheli, S. Loeb, and J.I. Epstein Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system J Urol 182 2009 1364 1370
16. J.I. Epstein, Z. Feng, B.J. Trock, and P.M. Pierorazio Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades Eur Urol 61 2012 1019 1024
17. A.W. Partin, J. Yoo, and H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110 114
18. D.V. Makarov, B.J. Trock, and E.B. Humphreys Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005 Urology 69 2007 1095 1101
19. Eifler JB, Feng Z, Lin BM, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. In press. http://dx.doi.org/10.1111/j.1464-410X.2012.11324.x.
20. M. Ohori, M.W. Kattan, and H. Koh Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer J Urol 171 2004 1844 1849 discussion 1849
21. M.R. Cooperberg, D.J. Pasta, and E.P. Elkin The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938 1942
22. B. Helpap, and L. Egevad Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens Anal Quant Cytol Histol 30 2008 133 138
23. A.J. Stephenson, P.T. Scardino, and J.A. Eastham Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Natl Cancer Inst 98 2006 715 717
24. M. Han, A.W. Partin, M. Zahurak, S. Piantadosi, J.I. Epstein, and P.C. Walsh Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 169 2003 517 523
25. H. Uemura, K. Hoshino, and T. Sasaki Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens BJU Int 103 2009 1190 1194
26. D.M. Berney, G. Fisher, and M.W. Kattan Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading BJU Int 100 2007 1240 1244
27. B. Delahunt, D.S. Lamb, and J.R. Srigley Gleason scoring: a comparison of classical and modified (International Society of Urological Pathology) criteria using nadir PSA as a clinical end point Pathology 42 2010 339 343
28. M. Graefen, P.I. Karakiewicz, and I. Cagiannos Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer J Clin Oncol 20 2002 951 956
29. D.J. Hernandez, M.E. Nielsen, and M. Han Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy Urology 72 2008 172 176
30. Pierorazio PM, Walsh PC, Partin AW, et al. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. J Urol. In press.
31. T.Y. Chan, A.W. Partin, P.C. Walsh, and J.I. Epstein Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy Urology 56 2000 823 827
32. W.K. Lau, M.L. Blute, D.G. Bostwick, A.L. Weaver, T.J. Sebo, and H. Zincke Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4 J Urol 166 2001 1692 1697
33. J.R. Stark, S. Perner, and M.J. Stampfer Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27 2009 3459 3464
34. L. Egevad, T. Granfors, L. Karlberg, A. Bergh, and P. Stattin Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection J Urol 168 2002 509 513
35. T.A. Stamey, J.E. McNeal, C.M. Yemoto, B.M. Sigal, and I.M. Johnstone Biological determinants of cancer progression in men with prostate cancer JAMA 281 1999 1395 1400
36. S.E. Eggener, P.T. Scardino, and P.C. Walsh Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 2011 869 875
37. A.N. Vis, S. Roemeling, R. Kranse, F.H. Schroder, and T.H. van der Kwast Should we replace the Gleason score with the amount of high-grade prostate cancer? Eur Urol 51 2007 931 939
38. E.S. Antonarakis, Z. Feng, and B.J. Trock The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up BJU Int 109 2012 32 39
39. D.C. Chade, S.F. Shariat, and A.M. Cronin Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration Eur Urol 60 2011 205 210
40. F. Brimo, A.W. Partin, and J.I. Epstein Tumor grade at margins of resection in radical prostatectomy specimens is an independent predictor of prognosis Urology 76 2010 1206 1209
41. D. Cao, A.S. Kibel, F. Gao, Y. Tao, and P.A. Humphrey The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence Am J Surg Pathol 34 2010 994 1001
42. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
43. K.A. Hinnen, and M. van Vulpen Predictors in the outcome of 125I brachytherapy as monotherapy for prostate cancer Expert Rev Anticancer Ther 11 2011 115 123
44. S.J. Frank, P.D. Grimm, and J.E. Sylvester Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States Brachytherapy 6 2007 2 8
45. N.N. Stone, M.M. Stone, B.S. Rosenstein, P. Unger, and R.G. Stock Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy J Urol 185 2011 495 500
46. A.V. Taira, G.S. Merrick, and R.W. Galbreath Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 82 2012 e225 e232
47. R.G. Stock, J.A. Cesaretti, and N.N. Stone Disease-specific survival following the brachytherapy management of prostate cancer Int J Radiat Oncol Biol Phys 64 2006 810 816
48. Z.A. Alicikus, Y. Yamada, and Z. Zhang Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer Cancer 117 2011 1429 1437
49. R.D. Tendulkar, C.A. Reddy, and K.L. Stephans Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy Int J Radiat Oncol Biol Phys 82 2012 1397 1404
50. M.H. Stenmark, K. Blas, S. Halverson, H.M. Sandler, F.Y. Feng, and D.A. Hamstra Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease Int J Radiat Oncol Biol Phys 81 2011 e335 e344
51. A.A. Patel, M.H. Chen, A.A. Renshaw, and A.V. D'Amico PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5 JAMA 298 2007 1533 1538
52. A. Sabolch, F.Y. Feng, and S. Daignault-Newton Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation Int J Radiat Oncol Biol Phys 81 2011 e351 e360
53. A. Dal Pra, F.L. Cury, and L. Souhami Combining radiation therapy and androgen deprivation for localized prostate cancer - a critical review Curr Oncol 17 2010 28 38
54. J.I. Epstein, P.C. Walsh, M. Carmichael, and C.B. Brendler Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
55. M.A. Dall'Era, B.R. Konety, and J.E. Cowan Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 112 2008 2664 2670
56. N. Lawrentschuk, and L. Klotz Active surveillance for low-risk prostate cancer: an update Nat Rev Urol 8 2011 312 320
57. T.B. Sheridan, H.B. Carter, W. Wang, P.B. Landis, and J.I. Epstein Change in prostate cancer grade over time in men followed expectantly for stage T1c disease J Urol 179 2008 901 904 discussion 904-5
58. J.J. Tosoian, B.J. Trock, and P. Landis Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185 2190
59. J.S. Jones, J.C. Rewcastle, B.J. Donnelly, F.M. Lugnani, L.L. Pisters, and A.E. Katz Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry J Urol 180 2008 554 558
60. P.E. Spiess, A.E. Katz, and J.L. Chin A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer BJU Int 106 2010 194 198
61. P.E. Spiess, R.W. Given, and J.S. Jones Achieving the 'bifecta' using salvage cryotherapy for locally recurrent prostate cancer: analysis of the Cryo On-Line Data (COLD) Registry data BJU Int 110 2012 217 220
62. S. Crouzet, X. Rebillard, and D. Chevallier Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients Eur Urol 58 2010 559 566
63. X. Rebillard, M. Soulie, and E. Chartier-Kastler High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology BJU Int 101 2008 1205 1213
64. P. Ryan, A. Finelli, and N. Lawrentschuk Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue J Clin Pathol 65 2012 729 734
65. S.E. Eggener, P.T. Scardino, and P.R. Carroll Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities J Urol 178 2007 2260 2267
66. J. de la Rosette, H. Ahmed, and J. Barentsz Focal therapy in prostate cancer - report from a consensus panel J Endourol 24 2010 775 780
67. A.B. El Fegoun, E. Barret, and D. Prapotnich Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up Int Braz J Urol 37 2011 213 219